WAYNE, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that the largest U.S. healthcare claims and utilization analysis for benign prostatic hyperplasia (BPH) ...

“Arriving at the intersection of effective BPH treatment, patient priorities and available technology can be a daunting task,” said Mr. Olly Kayes, MD, Honorary Senior Lecturer at the University of ...

Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.

For patients with benign prostatic hyperplasia (BPH), there are several options when to comes to surgical treatment. A comparison of real-world outcomes reveals significant differences in ...

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of ...

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced the results of an independent analysis measuring costs and ...

WAYNE, Pa.--(BUSINESS WIRE)--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Sponsored content: Enlarged prostate affects ...

NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...